Of the 23 chronic myeloid leukemia (CML) patients in the four highest dosing groups, 19 remain on study without disease progression, evidence of control of their disease, Ariad said.

All the patients have previously been treated with the currently available first- and second-generation targeted therapies for CML, the company said in a statement.

Merriman Curhan Ford analyst Joe Pantginis, who maintained his "neutral" rating on the stock, termed the AP24534 compound as a "long-term promise" in his research note.

In the trial, thirty-two patients have been enrolled to date of the about 50 patients the company expects to enroll, the company said in a statement.

CML is characterized by an excessive and unregulated production of white blood cells by the bone marrow due to a genetic abnormality.

Ariad shares were up 41 percent at $2.43 in afternoon trade. They touched a high of $2.60 earlier in the session and were one of the top percentage gainers on Nasdaq.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites